Fig. 2

Evolution of central posterior hyaloid fibrosis (CPHF): Fig. 2A-D: This panel of images depicts the evolution of CPHF. At the first visit, the OCT scan shows a subfoveal macular neovascularization (MNV) of type 2 with SHRM with presence of associated subretinal fluid (Fig. 2A). This OCT scan shows no evidence of posterior vitreous separation. Visual acuity at this visit was 20/200. Evolution of CPHF: Figure 2A and D This image panel depicts the progression of central posterior hyaloid fibrosis (CPHF). At the first visit, the OCT scan reveals a subfoveal MNV of type 2 with SHRM and the presence of subretinal fluid (Fig. 2A) This OCT scan shows no evidence of posterior vitreous separation. Visual acuity was 20/200 at this visit. Five months after presentation, an OCT scan reveals a more fibrotic variant of subfoveal type 2 MNV with subretinal and intraretinal fluid (Fig. 2B). At this visit, a further decline in visual acuity to 20/400 was observed. No posterior vitreous detachment is seen. A 19-month follow-up OCT scan reveals the typical findings of CPHF (Fig. 2C) as described in Fig. 1. Vision is maintained at 20/400 at this time, as documented. At 18 months after the identification of CPHF at the most recent follow-up visit, the hyperreflectivity of the posterior hyaloid at the fovea has increased, while the remaining CPHF characteristics persist (Fig. 2D). At this visit, the visual acuity remains unchanged at 20/400. The patient received a total of two intravitreal anti-VEGF injections for that eye before the diagnosis of CPHF and one injection afterward